Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

Cipponi, Arcadi;Wieers, Grégoire;van Baren, Nicolas;Coulie, Pierre
(2011) Cancer Immunology Immunotherapy — Vol. 60, n° 8, p. 1153-1160 (2011)

Files

CIPPONI_CII2011.pdf
  • Restricted Access
  • Adobe PDF
  • 277.41 KB
Request a copy

Details

Authors
Abstract
Tumor-infiltrating T lymphocytes (TILs) are observed in a number of human primary or metastatic tumors. Recently, gene expression profiling experiments suggested that the presence of T cells in metastatic melanomas before vaccinating the patients with tumor antigens could be a biomarker for clinical benefit from the vaccines. In this context, we review results pertaining to TILs in human melanomas, their prognostic value, and some possible reasons why their presence could help in selecting melanoma patients for vaccination against tumor-specific antigens.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Cipponi, A., Wieers, G., van Baren, N., & Coulie, P. (2011). Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunology Immunotherapy, 60(8), 1153-1160. https://doi.org/10.1007/s00262-011-1026-2 (Original work published 2011)